Core Viewpoint - Tongyuan Kang Pharmaceutical-B (02410) experienced a significant stock increase, rising over 13% in early trading and currently up 8.94% at HKD 13.52, with a trading volume of HKD 40.7033 million [1] Group 1: Company Developments - The company announced that its investigational first-class new drug, Tazemetostat (TY-9591), has been included in the priority review list by the National Medical Products Administration (NMPA) [1] - Tazemetostat is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 substitution mutations, along with central nervous system metastases [1] - The inclusion in the priority review list signifies an acceleration in the review process for Tazemetostat, potentially leading to an earlier market launch and providing new treatment options for patients in China [1]

Core Viewpoint - Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, has announced that its HRS-5965 capsules are proposed to be included in the priority review list by the National Medical Products Administration (NMPA) of China, indicating a significant step towards potential market approval for a treatment targeting paroxysmal nocturnal hemoglobinuria in adults who have not previously received complement inhibitors [1] Drug Information - Drug Name: HRS-5965 Capsules [1] - Dosage Form: Capsule [1] - Applicant: Chengdu Shengdi Pharmaceutical Co., Ltd. [1] - Proposed Indication: Treatment for adult patients with paroxysmal nocturnal hemoglobinuria who have not previously received complement inhibitor therapy [1] Priority Review Justification - The application meets the requirements outlined in the "Drug Registration Management Measures" and the announcement regarding the "Review Procedures for Breakthrough Therapy Drugs" issued by the NMPA [1] - The drug is categorized under priority review for "clinically urgent shortage drugs, innovative drugs, and modified new drugs for the prevention and treatment of major infectious diseases and rare diseases" [1]